Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Division
HEAL Study
Title
Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder
Short Description
This pilot study examines the feasibility and acceptability of transitioning office-based buprenorphine treatment of opioid use disorder from physicians to pharmacists. Results from this study will inform the development of a future multi-site randomized clinical trial.
Release Date
Feb 16, 2023
Description

The overall objective of this study is to explore the feasibility of transitioning the care of adult patients with opioid use disorder (OUD) who receive office-based buprenorphine treatment (OBBT) from physicians to pharmacists. Physicians will induce buprenorphine treatment and complete the stabilization phase before referring patients to pharmacists for the management of monthly maintenance visits. This study will assess the feasibility and acceptability of a collaborative care model between physician and pharmacist by measuring recruitment rate, treatment retention rate, treatment compliance rate, and participants' substance use. Other assessments measured will include treatment fidelity, participant, physician, and pharmacist satisfaction with OUD care, participant safety, and the pharmacists' use of electronic health records and the Prescription Drug Monitoring Program.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents

Treatment Satisfaction Survey

Abbreviation
TSS
Description

Satisfaction with treatment delivery by participants will be measured using the Treatment Satisfaction Survey (adapted from Harland et al., 2005) at each visit. The proportion of visits in which participants are satisfied (score of 4 on a Likert Scale of 1-5) or very satisfied (score of 5 on a Likert Scale of 1-5) will be calculated.

Category
Health Cognitions & QOL
Division
HEAL Study
Title
Ph1 Marinol Interaction Study - Part 1
Short Description
Phase 1 Pilot Study To Examine The Cardiovascular Effects Of Smoked Marijuana, Interactions With Oral Dronabinol, And Effects Of Dronabinol On Withdrawal In Marijuana Dependent Volunteers - Part 1
Release Date
Nov 30, 2022
Description

This study will examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety, pharmacokinetics (PK), and cardiovascular effects of the combination of oral dronabinol and smoked marijuana to determine if there are potential significant drug interactions before conducting outpatient studies. Part One is a pilot study to characterize the cardiovascular effects/safety, subjective effects, and PK of smoked marijuana and to familiarize study staff with the conduct of controlled smoking sessions.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents

Marijuana Withdrawal Symptom Checklist

Abbreviation
MWSC
Description

The MWSC is a 10-item self-administered questionnaire developed by Budney et al. (1999). Each of the 10 items is a withdrawal symptom that is rated on a 4-point scale as follows: 0 = not at all; 1 = mild; 2 = moderate; 3 = severe. The 10 withdrawal symptoms include: 1) craving, 2) irritability, 3) nervousness, 4) depression, 5) anger, 6) restlessness, 7) sleep problems, 8) decreased appetite, 9) strange dreams, and 10) headaches. Symptoms will be evaluated individually and by computing a total withdrawal discomfort score (WDS) that is the sum of the individual item scores.

Category
Substance Use
Subcategory
Drugs